Dr. Sulaiman Al Habib Medical Services Group announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 2,521.41 | 2,306.87 | 9.3 | 2,486.49 | 1.404 |
| Gross Profit (Loss) | 877.33 | 783.64 | 11.955 | 868.16 | 1.056 |
| Operational Profit (Loss) | 556.07 | 510.57 | 8.911 | 534.18 | 4.097 |
| Net profit (Loss) | 550.95 | 489.27 | 12.606 | 525.01 | 4.94 |
| Total Comprehensive Income | 551.89 | 505.65 | 9.144 | 502.15 | 9.905 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Share Holders Equity (After Deducting the Minority Equity) | 6,634.88 | 6,058.84 | 9.507 |
| Profit (Loss) per Share | 1.57 | 1.4 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Percentage of the capital (%) | Amount | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | Revenues: for Q1 – 2024, revenues grew by 9.30%, reaching SAR 2,521.41 million, with an increase of SAR 214.54 million as compared to SAR 2,306.87 million in the corresponding quarter of the previous year, as a result of the growth in all group operating segments.
Revenue growth for Q1 – 2024 was mainly driven by growth in both the hospital and pharmacy segments. The increase in the hospital segment’s number of patients has a positive correlation with the pharmacy segment sales increase compared to the similar quarter of the previous year. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | EBITDA for Q1 – 2024 increased by 9.36%, reaching SAR 681.12 million. The group maintained the same EBITDA margin at 27.01%, compared to 27.00% in the corresponding quarter of the previous year.
Net Income for Q1 – 2024 increased by 12.61% to reach SAR 550.95 million, with an improved net income margin reaching 21.85% versus 21.21% for the corresponding quarter of the previous year. The increase was mainly driven by revenue growth due to the increase in the number of patients. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Revenue grew 1.40% during Q1 – 2024 compared to the previous quarter, Q4 – 2023, driven by the growth in the number of patients. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | Net income attributable to the company’s shareholders Increased by 4.94% in Q1 – 2024 compared to the previous quarter Q4–2023, which was mainly due to the growth in revenue. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | na |
| Reclassification of Comparison Items | na |
| Additional Information | na |
| Attached Documents |  |
Comments